Two years ago, Sue Prentiss got a sobering reality check at her doctor’s office. The news was blunt: She qualified for bariatric surgery, a procedure for patients whose weight poses life-threatening ...

Hims may have a chance to grow peptides business as a potential revenue driver, with FDA review in 2026 shaping the ...

The company argues the offering is a more comprehensive approach to weight management, allowing patients to receive ongoing ...

What to keep in mind if you're concerned about access to your medication.

A weight-loss drug is rewriting the American grocery list. Here's the condiment boom it created and the eating shift anyone ...

For Dr. Joseph Cacchione, the math on GLP-1 drugs stopped making sense.

Twelve million people lost coverage for Zepbound over the last year. The same number of people lost coverage for Wegovy, ...

The FDA has sent 30 warning letters to telehealth companies for falsely marketing compounded GLP-1s, which are not ...

"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." Peptides are all anyone wants ...

With an IPO raise of $625 million, Kailera Therapeutics now holds the new record for the largest public market debut.

Jim Cramer gave his latest thinking on all 31 stocks owned by the CNBC Investing Club, including Nvidia, Apple, and Microsoft ...

Medicare delayed a plan to make insurance companies cover GLP-1 drugs Wegovy and Zepbound. Instead, Medicare will cover the ...